Cue Biopharma, Inc.
New Form D on file · 2026-05-14 · the record
Cue Biopharma, Inc. filed a Form D with the Securities and Exchange Commission on 2026-05-14.
Cue Biopharma, Inc. filed a Form D notice of an exempt securities offering with the SEC on May 14, 2026. Cue Biopharma, Inc. trades on Nasdaq as CUE; it was formerly Imagen Biopharma, Inc. The filing reports $30M sold. Its industry group is Biotechnology. It names Shao-Lee Lin (Executive Officer, Director), Colin Sandercock (Executive Officer), Daniel Baker (Executive Officer) (SEC Form D, May 14, 2026).
In its own words: “CUE Biopharma is a clinical-stage biopharmaceutical company focused on advancing a robust portfolio of therapies.” (cuebiopharma.com, checked October 31, 2026)
Sell to companies like Cue Biopharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
88 companies raised this week, 1 had other signals.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| fal - Features & Labels, Inc. | $1B | AI and software |
| fal - Features & Labels, Inc. | $350M | AI and software |
| SIERRA INTERNATIONAL NETWORK INC | $300M | AI and software |
| Zai Lab Ltd | $250M | Biotech |
| Databento Inc. | $100M | AI and software |
Is this your company?
New Form D on file · 2026-05-14 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Cue Biopharma, Inc.
Free to see. No signup.
More on the people and the money behind Cue Biopharma, Inc., from the filings we hold.
Newbridge Securities Corporation received sales compensation on this raise and on 2 other raises we hold, nearest in date first:
Biotechnology raises by companies based in Massachusetts, filed in May 2026, largest first.
Get an email when Cue Biopharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Cue Biopharma, Inc. raises, hires or launches. No email unless you switch it on.
Watch Cue Biopharma, Inc. →Get the full cited report on Cue Biopharma, Inc.
What the filing shows about Cue Biopharma, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cue Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The weeks after a raise are when investors, other founders and press look Cue Biopharma, Inc. up. FoxPlug is your startup's chief of staff: it reads your whole stack and tells you what to fix, what to say and what to skip, for founders shipping with Claude Code, Codex or Cursor. It drafts your monthly investor update from your real numbers, and its free tools need no account. GetFoxChat puts an AI operator on Cue Biopharma, Inc.'s own site, named as you like, so the visitors this record sends you don't read one page and leave.
The filing gives Cue Biopharma, Inc.'s address as 40 Guest Street, Boston, MA 02135.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Cue Biopharma, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Cue Biopharma, Inc. is a registered filer with the SEC (CIK 1645460) and has filed since 2022-11-21. 3 filings are on record, the latest on 2026-07-22.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Cue Biopharma, Inc.'s Form D of 2026-05-14 names Shao-Lee Lin, Colin Sandercock, Daniel Baker and 6 more as its officers, directors or promoters.
Its new offerings report $110M sold across 3 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $30M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Shao-Lee Lin is named as Executive Officer and Director on the Form D that Cue Biopharma, Inc. filed with the SEC on 14 May 2026, one of 9 people that filing names.
Colin Sandercock is named as Executive Officer on the Form D that Cue Biopharma, Inc. filed with the SEC on 14 May 2026, one of 9 people that filing names.
Daniel Baker is named as Executive Officer on the Form D that Cue Biopharma, Inc. filed with the SEC on 14 May 2026, one of 9 people that filing names.
Pasha Sarraf is named as Director on the Form D that Cue Biopharma, Inc. filed with the SEC on 14 May 2026, one of 9 people that filing names.
Frank Morich is named as Director on the Form D that Cue Biopharma, Inc. filed with the SEC on 14 May 2026, one of 9 people that filing names.
Peter Kiener is named as Director on the Form D that Cue Biopharma, Inc. filed with the SEC on 14 May 2026, one of 9 people that filing names.
Patrick Verheyen is named as Director on the Form D that Cue Biopharma, Inc. filed with the SEC on 14 May 2026, one of 9 people that filing names.
Pamela Garzone is named as Director on the Form D that Cue Biopharma, Inc. filed with the SEC on 14 May 2026, one of 9 people that filing names.
Jill Broadfoot is named as Director on the Form D that Cue Biopharma, Inc. filed with the SEC on 14 May 2026, one of 9 people that filing names.
9 people named on the filing — 3 holding an executive role and 6 as directors only.
Named as of the 2026-05-14 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Cue Biopharma, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cue Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cue Biopharma, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Cue Biopharma, Inc.You get an alert in MentionFox the next time this company shows up.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Cue Biopharma, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Boston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.

https://mentionfox.com/funding/cue-biopharma-inc-form-d-26000001